Overview
- Medicare will begin covering certain GLP-1 obesity medicines next year, with qualifying beneficiaries paying $50 monthly copays, according to the administration.
- Direct-to-consumer discounts via the TrumpRx program will offer some injectable brands for as low as $350 per month, with sales set to start in January, per the White House.
- If the FDA clears oral GLP-1 pills, the initial dose would launch at about $149–$150 per month under the terms outlined by officials.
- Eli Lilly and Novo Nordisk also agreed to provide lower prices to state Medicaid programs, though timing and specifics will depend on state negotiations.
- Officials say the move responds to soaring demand and affordability concerns for GLP-1 drugs such as Zepbound and Wegovy, even as the ultimate savings for consumers remain uncertain.